Abstract | RATIONALE: OBJECTIVES: To use mass spectrometry to determine which plasma sphingolipids are associated with subphenotypes of COPD. METHODS: One hundred twenty-nine current and former smokers from the COPDGene cohort had 69 distinct sphingolipid species detected in plasma by targeted mass spectrometry. Of these, 23 were also measured in 131 plasma samples (117 independent subjects) using an untargeted platform in an independent laboratory. Regression analysis with adjustment for clinical covariates, correction for false discovery rate, and metaanalysis were used to test associations between COPD subphenotypes and sphingolipids. Peripheral blood mononuclear cells were used to test associations between sphingolipid gene expression and plasma sphingolipids. MEASUREMENTS AND MAIN RESULTS: CONCLUSIONS:
|
Authors | Russell P Bowler, Sean Jacobson, Charmion Cruickshank, Grant J Hughes, Charlotte Siska, Daniel S Ory, Irina Petrache, Jean E Schaffer, Nichole Reisdorph, Katerina Kechris |
Journal | American journal of respiratory and critical care medicine
(Am J Respir Crit Care Med)
Vol. 191
Issue 3
Pg. 275-84
(Feb 01 2015)
ISSN: 1535-4970 [Electronic] United States |
PMID | 25494452
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Biomarkers
- Glycosphingolipids
- Sphingomyelins
- Trihexosylceramides
- dihexosylceramide
|
Topics |
- Biomarkers
(blood)
- Gene Expression Regulation
- Glycosphingolipids
(blood)
- Humans
- Leukocytes, Mononuclear
(metabolism)
- Mass Spectrometry
- Phenotype
- Predictive Value of Tests
- Pulmonary Disease, Chronic Obstructive
(blood, diagnosis)
- Pulmonary Emphysema
(blood, diagnosis)
- Risk Factors
- Sensitivity and Specificity
- Severity of Illness Index
- Smoking
(adverse effects)
- Sphingomyelins
(blood)
- Trihexosylceramides
(blood)
|